The Detroit Division

DEA Detroit Division

Last fully verified: July 24, 2026

The Drug Enforcement Administration’s Detroit Division serves Michigan, Ohio, and a portion of northern Kentucky.

That jurisdiction requires careful explanation.

DEA’s main Detroit Division page describes the division as serving only Michigan and Ohio. Current operational records tell a broader story. Special Agent in Charge Joseph O. Dixon’s official biography states that he oversees DEA operations throughout Michigan, Ohio, and northern Kentucky. A January 2026 division-wide enforcement report uses the same three-part jurisdictional description. The stronger contemporary record therefore supports including northern Kentucky, while preserving the contradiction in DEA’s own public materials.

The exact county-by-county northern Kentucky boundary is not published in the current public sources reviewed for this page. DEA’s Detroit contact page also lists no Kentucky office or direct Kentucky telephone number.

For those reasons, this page will not invent a boundary, assign particular Kentucky counties to the division without evidence, or present statewide Kentucky prescribing data as though it measured the Detroit Division’s limited Kentucky jurisdiction.

Within Michigan and Ohio, DEA publicly lists contact locations in Detroit, Flint, Grand Rapids, Kalamazoo, Lansing, Marquette, and Traverse City, Michigan, and Cincinnati, Cleveland, Columbus, Dayton, Toledo, and Youngstown, Ohio.

The Detroit Division investigates illicit drug trafficking, transnational criminal organizations, violent drug networks, money laundering, fentanyl distribution, and other federal offenses. It also administers and enforces the federal controlled-substance system governing lawful manufacturers, distributors, pharmacies, hospitals, treatment programs, physicians, nurses, researchers, and other DEA registrants.

This page concerns that lawful system.

It explains who leads the division, which offices and personnel are publicly identified, how diversion-control authority operates across the region, how federal and state regulatory systems overlap, what actual diversion cases look like, and what the available prescribing record can—and cannot—prove about medicine in Michigan, Ohio, and northern Kentucky.

The Name Matters

The official regional organization is the DEA Detroit Division.

It is not formally called the “Detroit Diversion Division.”

The Detroit Division is a regional DEA field division responsible for multiple enforcement missions. Pharmaceutical diversion control is one component of that broader command.

The national Diversion Control Division is a separate operational component within DEA headquarters. It administers national programs involving controlled-substance registration, regulatory policy, production quotas, imports and exports, listed chemicals, distribution monitoring, resource allocation, and major diversion investigations.

The two organizations are connected, but they are not interchangeable.

National DEA components create and administer much of the federal framework. Detroit Division personnel implement and enforce portions of that framework within the division’s regional jurisdiction.

The Detroit Division does not independently:

• Enact the Controlled Substances Act;
• Establish national manufacturing quotas;
• Write national DEA regulations;
• Create CDC clinical recommendations;
• Issue Michigan, Ohio, or Kentucky medical licenses;
• Establish every hospital, pharmacy, or insurance policy affecting pain care;
• Determine the national medical standard of care.

Its personnel can, however:

• Inspect DEA registrants;
• Examine controlled-substance records;
• Audit inventories;
• Investigate thefts and losses;
• Investigate suspected unlawful prescribing or dispensing;
• Coordinate with state regulators and law-enforcement agencies;
• Execute warrants when legally authorized;
• Support administrative proceedings;
• Refer civil or criminal matters for prosecution.

National policy should not be attributed solely to one field division.

A field division should also not be treated as irrelevant when its personnel possess federal authority over the lawful controlled-substance channel.

Who This Division Serves

Michigan

The Detroit Division serves the entire State of Michigan.

DEA publishes contact locations in:

• Detroit
• Flint
• Grand Rapids
• Kalamazoo
• Lansing
• Marquette
• Traverse City

The division’s Michigan territory includes the Detroit metropolitan area, mid-Michigan, western Michigan, the northern Lower Peninsula, and the Upper Peninsula.

These areas differ significantly in population density, hospital access, specialist availability, pharmacy coverage, transportation, insurance participation, and distance from major medical centers.

A patient in central Detroit does not necessarily encounter the same medical environment as a patient in Marquette, Traverse City, Flint, or a remote Upper Peninsula community.

Statewide figures therefore provide a broad statewide measure. They do not describe every local treatment environment.

Ohio

The Detroit Division also serves the entire State of Ohio.

DEA publishes contact locations in:

• Cincinnati
• Cleveland
• Columbus
• Dayton
• Toledo
• Youngstown

Ohio contains several major metropolitan healthcare markets, extensive suburban communities, Appalachian counties, industrial regions, agricultural areas, and communities positioned along major interstate transportation corridors.

As in Michigan, statewide prescribing figures conceal substantial local differences.

The availability of a specialist, hospital pain service, independent pharmacy, addiction-treatment provider, cancer center, or palliative-care program can vary greatly from one county to another.

Northern Kentucky

Current DEA leadership and operational records include northern Kentucky within the Detroit Division’s jurisdiction. DEA’s main Detroit page does not.

The reviewed official sources do not publish:

• A county-by-county northern Kentucky boundary;
• A Detroit Division office located in Kentucky;
• A direct northern Kentucky contact number;
• A public explanation of how Kentucky responsibilities are divided between the Detroit and Louisville field divisions.

That absence limits what can responsibly be stated.

This page therefore recognizes northern Kentucky as part of the current operational jurisdiction while refusing to create a more exact geographical description than DEA has publicly supported.

Statewide Kentucky statistics will not be presented as Detroit Division statistics. Most of Kentucky lies outside the division.

Headquarters

The Detroit Division headquarters is publicly listed at:

DEA Detroit Division
431 Howard Street
Detroit, Michigan 48226

Main telephone: (313) 234-4000

The headquarters coordinates division-wide operations and serves as the division’s principal public contact location.

Current Leadership

Joseph O. Dixon

Special Agent in Charge

As of July 24, 2026, Joseph O. Dixon is the publicly identified Special Agent in Charge of the DEA Detroit Division.

Dixon assumed the position on October 5, 2025. DEA states that he oversees all agency operations in Michigan, Ohio, and northern Kentucky.

Dixon began his DEA career in October 2010 in the Detroit Division. His early federal work included investigations involving violent drug organizations and participation in regional violent-crime initiatives.

He transferred to DEA’s Miami Field Division in 2011, where he investigated transnational drug-trafficking organizations, violent criminal groups, and corrupt public officials. His responsibilities included liaison work involving the Bahamas and Turks and Caicos.

From July 2016 through May 2018, Dixon served on DEA’s Executive Protection Detail and later performed duties as Acting Unit Chief.

In August 2019, he helped lead Department of Justice violent-crime initiatives in Detroit, including Operation Relentless Pursuit and Operation LeGend.

Dixon became the Senior Supervisory Special Agent of DEA’s Grand Rapids District Office in December 2019. DEA states that he oversaw five Michigan offices and served as commander of a western Michigan High Intensity Drug Trafficking Area task force.

He later served as an inspector in DEA’s Office of Professional Responsibility beginning in October 2022 and became an Assistant Special Agent in Charge of the St. Louis Division in November 2023.

Before joining DEA, Dixon spent eight years as a police officer and detective and four years as a DEA task-force officer.

He holds a bachelor’s degree in criminology and criminal justice from Eastern Michigan University and has completed leadership programs associated with the University of Virginia and Michigan law-enforcement organizations.

Dixon’s official biography documents extensive experience in criminal investigations, violent-crime initiatives, international liaison work, internal professional responsibility, task-force leadership, and field-office management.

It does not identify him as a physician, pharmacist, epidemiologist, pain specialist, or clinical researcher.

That distinction does not diminish his legal authority. It identifies the professional perspective from which the division is led.

An Official-Record Discrepancy

DEA’s public record does not present one consistent description of the Detroit Division’s jurisdiction.

The main division page states:

Serving Ohio and Michigan.

Dixon’s current official biography states that he oversees:

Michigan, Ohio, and northern Kentucky.

A January 29, 2026, DEA report describing division operations likewise identifies Michigan, Ohio, and northern Kentucky.

The contemporary biography and operational release are stronger evidence of the present jurisdiction than the shorter introductory line on the division page.

The contradiction should nevertheless remain visible.

A reader should not have to choose between silently accepting an incomplete agency page and inventing an explanation the agency has not supplied.

Official websites are evidence.

They are not automatically synchronized, complete, or free from error.

Publicly Identified Personnel

DEA does not publish a complete roster of Detroit Division special agents, diversion investigators, intelligence analysts, task-force officers, supervisors, attorneys, or administrative personnel.

Seeds of Vice will not manufacture one from:

• Social-media profiles;
• Commercial databases;
• Old press releases;
• Undated biographies;
• Former assignments;
• Unverified directories;
• Assumptions based on job titles.

The following people are included because DEA currently identifies them in active public-facing roles.

Brian McNeal

Media Inquiries and Community Outreach

DEA lists Brian McNeal as both the Detroit Division media contact and its community-outreach contact.

Telephone: (571) 362-1498
Email: Brian.K.McNeal@dea.gov

Media and community-outreach responsibilities are distinct from command of diversion investigations.

A public-information or outreach role should not be interpreted as evidence that the person supervises Tactical Diversion Squads, registration inspections, or prescribing investigations.

Kimberly A. Tozer

Internship and Volunteer Contact

DEA lists Kimberly A. Tozer as the Detroit Division contact for non-agent internship and volunteer opportunities.

Telephone: (571) 362-1858

Special Agent Recruitment

DEA currently publishes a general Detroit Division recruitment contact rather than naming an individual recruiter.

Telephone: (571) 362-1858
Email: DetroitSpecialAgentRecruiter@dea.gov

No Complete Diversion Roster

DEA’s current Detroit page does not publicly identify:

• Every Assistant Special Agent in Charge;
• Every district-office supervisor;
• Every diversion program manager;
• Every Tactical Diversion Squad supervisor;
• Every diversion investigator;
• A current named Diversion Outreach Coordinator.

The absence of a public name does not establish that a role is vacant.

It means the current public record does not support publishing the person’s identity.

Public Contact Locations

Michigan

Detroit Headquarters
(313) 234-4000

Flint
(810) 768-7600

Grand Rapids
(616) 458-0616

Kalamazoo
(571) 362-0443

Lansing
(571) 362-1194

Marquette
(571) 362-0443

Traverse City
(571) 362-0443

Ohio

Cincinnati
(513) 684-3671

Cleveland
(216) 274-3600

Columbus
(614) 255-4200

Dayton
(937) 291-1988

Toledo
(419) 259-6490

Youngstown
(330) 740-7000

DEA’s page includes a legend describing possible office classifications, but the text version does not clearly assign each listed city a specific classification.

Accordingly, this page calls them publicly listed contact locations except where a separate official record explicitly identifies an office.

A public telephone listing does not establish:

• Staffing levels;
• Internal reporting relationships;
• Exact territorial boundaries;
• Whether diversion personnel are permanently assigned there;
• Whether the location is a district office, resident office, post of duty, satellite office, or another organizational unit.

Those details should not be inferred without supporting evidence.

The Division’s Broader Enforcement Mission

The Detroit Division’s work extends far beyond pharmaceutical diversion.

DEA reported that its personnel in Michigan, Ohio, and northern Kentucky seized during 2025:

• 147 kilograms of fentanyl;
• 432 kilograms of counterfeit pills;
• 1,658 kilograms of cocaine;
• 1,054 kilograms of methamphetamine;
• 324 firearms;
• More than $17 million in cash and assets.

DEA also reported approximately 950 arrests during the year.

Those figures concern the division’s broader enforcement mission.

They should not be used to imply that every controlled substance encountered by the division came from a doctor, pharmacy, hospital, or lawful manufacturer.

Illicitly manufactured fentanyl, counterfeit tablets, cartel-supplied drugs, stolen pharmaceuticals, and legitimately prescribed medicine are different categories.

A system that fails to distinguish them risks turning the existence of illicit trafficking into a presumption against lawful patients.

Diversion-Control Infrastructure

DEA’s current Tactical Diversion Squad directory identifies squads in:

Michigan

• Detroit

Ohio

• Cleveland
• Columbus

The directory lists Kentucky squads in London and Louisville, but it does not identify either one as a Detroit Division unit. The existence of those squads should not be used to infer the precise diversion structure serving northern Kentucky.

A Tactical Diversion Squad is an enforcement-oriented, multiagency unit.

DEA states that these squads combine agency personnel with federal, state, and local participants to investigate organizations and individuals suspected of violating controlled-substance or listed-chemical laws. They can support traditional diversion groups with law-enforcement capabilities such as:

• Physical surveillance;
• Controlled purchases of evidence;
• Recruitment and management of confidential sources;
• Payment of informants;
• Arrest operations;
• Search-warrant execution;
• Evidence seizures;
• Coordination across jurisdictions.

This structure matters because diversion control can move along a continuum.

A matter may begin with:

• A registration issue;
• A compliance inspection;
• An inventory discrepancy;
• A theft or significant-loss report;
• A suspicious-order report;
• An unusual prescribing or dispensing pattern;
• A complaint from an employee, patient, pharmacist, or healthcare institution;
• Information from a professional licensing board;
• Information from another law-enforcement agency.

If investigators believe the evidence supports criminal conduct, the matter can become a conventional criminal investigation involving surveillance, informants, warrants, arrests, and prosecution.

That does not mean every inspection becomes a criminal case.

It means the diversion system possesses both regulatory and criminal enforcement capacity.

Traditional Diversion Work

Diversion investigators are regulatory specialists whose work can include:

• Registration matters;
• Compliance inspections;
• Controlled-substance inventories;
• Ordering and distribution records;
• Theft and loss reports;
• Prescription records;
• Security requirements;
• Suspicious-order monitoring;
• Administrative cases;
• Interviews with registrants and employees;
• Coordination with state licensing authorities.

Tactical Diversion Squads add criminal-investigative capabilities to that regulatory framework.

The coexistence of both models reflects the unusual character of diversion control.

It governs a lawful medical and commercial system, yet suspected violations can result in:

• Corrective education;
• Administrative restrictions;
• Civil penalties;
• Registration surrender;
• Professional discipline;
• Search warrants;
• Arrests;
• Criminal prosecution.

A physician, hospital, pharmacy, treatment program, distributor, or employee may therefore encounter DEA through very different legal pathways.

The Federal and State Layers

Controlled-substance practice within the Detroit Division is governed by overlapping institutions.

A practitioner may require:

• A state professional license;
• State controlled-substance authority where applicable;
• Federal DEA registration;
• Compliance with state prescribing law;
• Compliance with federal prescribing law;
• Participation in or consultation of a prescription-monitoring program;
• Hospital or health-system credentials;
• Pharmacy acceptance;
• Insurance authorization;
• Compliance with professional-board standards.

Those requirements arise from different institutions.

They should not all be attributed to DEA.

They should also not be treated as unrelated when their combined effect determines whether a lawful patient receives medicine.

Michigan Automated Prescription System

Michigan’s prescription-monitoring program is called the Michigan Automated Prescription System, or MAPS.

MAPS tracks Schedule II through Schedule V controlled substances dispensed in or into Michigan. The state describes it as a tool for prescribers, pharmacists, and other authorized users to review controlled-substance histories and identify potential risks.

Michigan established the modern system in 2003. State guidance requires covered dispensations of Schedule II through Schedule V substances to be reported. Licensed prescribers must register with MAPS before prescribing or dispensing those controlled substances.

Michigan generally requires a prescriber to obtain and review a MAPS report before prescribing more than a three-day supply of a controlled substance, subject to legal exceptions.

Michigan law and guidance also address:

• A bona fide prescriber-patient relationship;
• Opioid education;
• Patient acknowledgment forms;
• Electronic prescribing;
• Limits involving acute-pain prescriptions;
• Exceptions for particular circumstances.

MAPS is a Michigan state system.

It should not be mislabeled as a DEA database.

DEA may obtain or use relevant information through lawful investigative processes, but state administration and federal enforcement remain institutionally distinct.

Ohio Automated Rx Reporting System

Ohio’s prescription-monitoring program is the Ohio Automated Rx Reporting System, or OARRS.

OARRS collects information concerning outpatient controlled-substance prescriptions dispensed in Ohio. Authorized access can include prescribers, pharmacists, professional regulatory bodies, and law-enforcement personnel conducting qualifying investigations.

Ohio requires covered prescribers of opioid analgesics and benzodiazepines, as well as pharmacists dispensing controlled substances, to register for OARRS access.

Before initially prescribing an opioid analgesic or benzodiazepine, a prescriber generally must request and review the patient’s preceding 12 months of OARRS information, subject to exceptions. For treatment continuing beyond 90 days, Ohio generally requires another report at intervals no greater than 90 days.

Ohio’s requirements also address cross-border practice.

A prescriber located in an Ohio county adjoining another state may be required to obtain information from the adjoining state’s monitoring system when that information is relevant and available. Kentucky is among the neighboring states identified in Ohio’s guidance.

That cross-border structure is particularly relevant to a division whose current jurisdiction includes northern Kentucky.

OARRS remains an Ohio state system.

It is not the same institution as DEA, even though information from state monitoring systems may become relevant in federal investigations.

Kentucky All Schedule Prescription Electronic Reporting

Kentucky’s monitoring program is known as KASPER, the Kentucky All Schedule Prescription Electronic Reporting system.

Kentucky requires pharmacies and covered dispensing practitioners to report controlled-substance dispensing information generally within one business day. Authorized prescribers, pharmacists, regulators, and other legally permitted users can review prescription histories and related information.

KASPER is administered by Kentucky, not by the Detroit Division.

Because only northern Kentucky falls within the Detroit Division’s current operational jurisdiction, statewide KASPER patterns cannot automatically be treated as divisional patterns.

The overlap does, however, illustrate how a patient or practitioner near the Ohio–Kentucky border may encounter:

• Kentucky licensing and monitoring requirements;
• Ohio cross-border review requirements;
• Federal DEA registration;
• A Detroit Division field jurisdiction;
• Other institutional policies imposed by pharmacies, insurers, or health systems.

Permission is layered.

The patient experiences the combined result.

The Official Diversion-Control Mission

DEA’s Diversion Control Division describes its mission as preventing, detecting, and investigating the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.

That is a dual obligation.

Prevent Diversion

DEA is responsible for protecting the lawful channel from conduct such as:

• Theft;
• Fraud;
• Forgery;
• Record falsification;
• Employee diversion;
• Unlawful prescribing;
• Unlawful dispensing;
• Improper distribution;
• Security failures;
• Suspicious ordering;
• Other transfers from lawful possession into unlawful use.

Preserve Legitimate Supply

DEA also accepts responsibility for ensuring that controlled substances remain available for legitimate purposes, including:

• Surgery;
• Emergency medicine;
• Cancer treatment;
• Palliative and end-of-life care;
• Treatment of acute and chronic pain;
• Treatment of substance-use disorders;
• Veterinary medicine;
• Scientific research;
• Pharmaceutical manufacturing;
• Other lawful commercial purposes.

The mission is not written as preventing diversion regardless of the consequences to legitimate medicine.

Both responsibilities matter.

A complete evaluation must ask not only what was seized, stopped, surrendered, revoked, or prosecuted.

It must also ask whether legitimate patients, practitioners, hospitals, pharmacies, researchers, and manufacturers could obtain an adequate and uninterrupted lawful supply.

The Closed System of Distribution

Federal controlled-substance law operates through what DEA calls a closed system of distribution.

Manufacturers, distributors, importers, exporters, pharmacies, hospitals, healthcare professionals, researchers, and other lawful handlers generally must be registered or otherwise authorized.

Registrants must comply with applicable requirements concerning:

• Security;
• Inventories;
• Ordering;
• Records;
• Prescribing;
• Dispensing;
• Theft and loss reporting;
• Suspicious orders;
• Transfers;
• Disposal;
• Imports and exports.

DEA registration is not ceremonial.

For many practitioners and businesses, it is the federal permission required to participate in the controlled-substance channel.

A physician may hold a state medical license but still require DEA registration to prescribe federally controlled substances.

A pharmacy may possess state authority but still require federal registration to handle them.

A hospital depends upon registered suppliers, pharmacies, and practitioners.

A patient experiences the closed system through every authorized participant standing between manufacturing and medical use.

What the Detroit Division Can Do

Depending on the evidence and applicable legal process, Detroit Division personnel can:

• Conduct regulatory inspections;
• Review controlled-substance records;
• Audit inventories;
• Examine ordering and distribution patterns;
• Investigate thefts and significant losses;
• Interview registrants and employees;
• Investigate prescribing and dispensing;
• Work with state professional boards;
• Coordinate with local and federal law enforcement;
• Use subpoenas and other compulsory process;
• Conduct surveillance;
• Use confidential sources;
• Execute warrants;
• Seize evidence;
• Make arrests;
• Seek administrative action against a DEA registration;
• Refer civil or criminal matters to prosecutors.

The precise legal authority depends upon the type of investigation, the personnel involved, and the legal process being used.

What the Detroit Division Does Not Do

The Detroit Division does not ordinarily examine a pain patient, diagnose the cause of suffering, perform surgery, assess every treatment alternative, observe day-to-day functional improvement, or assume a clinician’s continuing duty of care.

DEA does not issue Michigan, Ohio, or Kentucky medical licenses.

It does not make every hospital credentialing decision.

It does not control every insurance authorization.

It does not make every pharmacy-level dispensing decision.

It does not write every pain contract, tapering policy, or clinic rule.

The Detroit Division therefore does not bear sole responsibility for every refused prescription, involuntary taper, pharmacy denial, untreated postoperative patient, or person unable to locate pain care in its jurisdiction.

Prescribers, pharmacists, insurers, health systems, corporate pharmacies, state licensing boards, legislatures, professional organizations, federal agencies, and individual clinical decisions can all affect access.

DEA nevertheless bears a distinct federal responsibility.

It controls entry into the federal registration system and possesses enforcement authority capable of influencing behavior far beyond the person or institution directly investigated.

That influence should not be exaggerated into sole causation.

It should not be minimized into irrelevance.

How Diversion Control Works in Practice

The clearest way to understand diversion control is to examine actual cases.

The following matters demonstrate different forms of alleged or proven diversion:

• Pharmacy dispensing and recordkeeping;
• Treatment-program controls;
• Corporate pharmacy practices;
• Criminal prescribing.

Their legal postures must remain distinct.

An allegation is not a conviction.

A consent decree is not automatically an admission of liability.

A settlement is not the same as a guilty plea.

A jury verdict is not merely an unresolved accusation.

Baldwin Pattie Drug Store

In January 2024, a federal court entered a consent decree requiring Baldwin Pattie Drug Store in Michigan to discontinue dispensing controlled substances.

The government alleged that the pharmacy stocked and promoted particular hydrocodone-acetaminophen tablets known as “yellow Norcos,” ordered them to gain a competitive advantage, and dispensed controlled substances to individuals the pharmacy allegedly had reason to believe were abusing drugs.

The government also alleged recordkeeping failures. A DEA audit reportedly identified thousands of opioid dosage units that could not be accounted for through the pharmacy’s records.

Under the resolution, the pharmacy surrendered its DEA registration and was permanently prohibited from dispensing controlled substances. The owner became subject to supervisory conditions involving future controlled-substance work, and the decree provided for a civil penalty within a specified range.

The claims were resolved through a consent decree without a judicial determination that every allegation was proven.

That distinction matters.

The case nevertheless demonstrates the regulatory questions diversion investigators may examine:

• Whether inventory records correspond to actual stock;
• Whether controlled substances are being selectively marketed;
• Whether dispensing patterns indicate known abuse;
• Whether the pharmacy maintains effective controls against diversion;
• Whether the registration should continue.

Sacred Heart Rehabilitation Center

In September 2024, Sacred Heart Rehabilitation Center agreed to a federal consent decree resolving allegations involving controlled substances at its Michigan treatment facilities.

The government alleged that some patients received controlled substances for withdrawal management before being evaluated by a properly authorized practitioner, sometimes for multiple days. It also alleged inaccurate records, failure to complete required inventories, and delayed reporting of thefts or significant losses.

The resolution required a $1 million civil penalty, enhanced compliance measures, and independent monitoring.

The investigation involved DEA’s Grand Rapids Diversion Group.

The consent decree did not constitute a judicial determination of every allegation.

The case remains important because treatment facilities occupy a sensitive position within the lawful channel.

They may possess controlled substances for medically vulnerable people while simultaneously operating under detailed federal requirements involving:

• Practitioner authority;
• Patient evaluation;
• Storage;
• Administration;
• Inventory;
• Records;
• Theft and loss reporting.

A treatment mission does not eliminate regulatory obligations.

Regulatory authority does not eliminate the duty to treat vulnerable patients humanely.

Both responsibilities exist.

Rite Aid

In July 2024, the federal government announced a resolution of nationwide Controlled Substances Act and False Claims Act allegations involving Rite Aid and affiliated entities.

The litigation was filed in the Northern District of Ohio, within the Detroit Division’s territory.

The government alleged that, from May 2014 through June 2019, Rite Aid pharmacies filled large numbers of controlled-substance prescriptions that lacked a legitimate medical purpose, were outside the usual course of professional practice, were medically unnecessary, or were otherwise invalid.

The resolution included a $7.5 million payment and an allowed government claim of approximately $401.8 million in Rite Aid’s bankruptcy proceedings.

This was a national corporate matter, not evidence that every prescription or pharmacy involved was located within the Detroit Division.

Its relevance lies in the role of the Northern District of Ohio and in the regulatory expectations applied to a major pharmacy chain operating throughout the region.

A corporate pharmacy can influence lawful access far beyond the individual prescription counter.

Its policies determine:

• Which prescriptions receive additional review;
• Which prescribers are treated as high risk;
• What stock is maintained;
• Whether unusual prescriptions are filled;
• What documentation is demanded;
• Whether a lawful patient must search elsewhere.

Corporate responsibility therefore runs in both directions.

A pharmacy should not blindly fill unlawful prescriptions.

It should also not convert regulatory caution into categorical abandonment of legitimate patients.

Dr. Saad Sakkal

In 2020, Ohio physician Saad Sakkal was sentenced to 20 years in federal prison after a jury convicted him of 30 counts of unlawfully distributing controlled substances outside the usual course of professional practice and without a legitimate medical purpose.

He was also convicted of six counts involving use of another person’s DEA registration number.

The government’s evidence included allegations of inadequate examinations, dangerous drug combinations, repeated warnings from pharmacists, information concerning addiction and overdose, and the death of a patient.

Because the matter resulted in a jury conviction, the criminal conduct established by the verdict is not merely an unresolved allegation.

The case represents the kind of conduct federal diversion law is intended to distinguish from legitimate medical practice.

It does not establish that:

• Every high-dose prescription is unlawful;
• Every long-term opioid treatment lacks a medical purpose;
• Every patient who develops physical dependence has been improperly treated;
• Every physician who disagrees with a population-level dosage recommendation is committing a crime.

A conviction based on case-specific evidence should not be transformed into a presumption against every other practitioner or patient.

What These Cases Establish

The official record establishes that diversion and controlled-substance violations can occur through different mechanisms.

They can involve:

• Missing pharmacy inventory;
• Inaccurate records;
• Dispensing despite signs of unlawful use;
• Failure to report thefts or losses;
• Administration before proper authorization or evaluation;
• Corporate dispensing failures;
• Use of another person’s registration number;
• Prescribing outside professional practice and without a legitimate medical purpose.

Those are legitimate subjects of investigation.

The cases do not establish that every unusual prescription is unlawful.

They do not establish that every patient receiving long-term treatment is a source of diversion.

They do not establish that a physician must abandon a patient merely because controlled-substance treatment carries regulatory risk.

Each case must turn on its own evidence.

Administrative, Civil, and Criminal Paths

Diversion matters do not all follow the same legal path.

A case may result in:

• Education or corrective action;
• A memorandum of agreement;
• Civil monetary penalties;
• A consent decree;
• Independent monitoring;
• Voluntary surrender of registration;
• An administrative order to show cause;
• Registration suspension or revocation;
• State professional discipline;
• Criminal charges;
• A guilty plea;
• Trial and conviction;
• No action if the evidence is insufficient.

These outcomes carry different meanings.

An administrative registration matter does not require the same process as a criminal prosecution.

A civil settlement does not automatically establish criminal guilt.

An indictment is an accusation.

A guilty plea or conviction establishes responsibility for the admitted or proven offenses.

Responsible publication must preserve those distinctions.

The Necessary Distinction

The following circumstances are not equivalent:

• A pharmacy failing to account for thousands of tablets;
• A physician using another person’s DEA registration number;
• A forged prescription;
• A falsified inventory;
• A doctor treating severe chronic pain;
• A surgeon treating acute postoperative pain;
• A palliative-care physician treating a dying patient;
• A treatment program administering properly authorized medication;
• A pharmacist resolving a lawful but unusual prescription;
• A patient physically dependent after long-term authorized therapy;
• A person selling medication illegally.

The controlled-substance framework exists in part to distinguish lawful possession, prescribing, dispensing, and use from unlawful conduct.

When diversion control preserves that distinction, it protects the lawful channel.

When suspicion becomes generalized, the lawful channel itself can become inaccessible.

How Enforcement Pressure Travels

Formal prosecutions are only the most visible part of the system.

Federal authority can affect conduct before an agent files a case.

A physician knows that DEA registration may be essential to practice.

A pharmacy knows its records and dispensing decisions may be reviewed.

A hospital knows missing medication can trigger federal scrutiny.

A treatment facility knows its inventories, practitioner authority, and administration records are regulated.

A distributor knows suspicious orders must be identified and reported.

Those realities create necessary safeguards.

They can also produce defensive behavior extending beyond what the law specifically requires.

A healthcare institution may impose an inflexible dosage ceiling.

A pharmacy may decline lawful prescriptions viewed as burdensome or risky.

A practitioner may stop accepting pain patients because controlled-substance care appears professionally dangerous.

A clinic may require drug testing, pill counts, treatment contracts, mandatory procedures, one-pharmacy rules, or immediate discharge for conduct not itself proven unlawful.

An insurer may convert a clinical recommendation into a rigid payment rule.

DEA does not necessarily order each of those actions.

The institution nevertheless operates within a regulatory environment partly shaped by federal registration and enforcement authority.

A rigorous analysis must distinguish among:

• Direct DEA action;
• State legal requirements;
• Professional-board rules;
• Corporate pharmacy policy;
• Hospital risk management;
• Insurance restrictions;
• Clinical judgment;
• Anticipatory compliance;
• Personal fear or prejudice.

Without those distinctions, one institution is blamed for everything while every institution avoids responsibility for its own decisions.

How This Affects Pain Patients and Lawful Medicine

Diversion control can protect patients.

It protects them when:

• Stolen medication is recovered;
• Tampered containers are discovered;
• Fraudulent prescriptions are stopped;
• Corrupt employees are identified;
• Institutional inventories become accurate;
• Controlled substances remain traceable;
• Prescribers acting outside legitimate practice are held accountable.

Control can also affect patients through the reactions of lawful institutions.

Patients may encounter:

• Difficulty finding a physician willing to treat pain;
• Difficulty finding a pharmacy willing or able to fill a prescription;
• Involuntary dosage reductions;
• Abrupt discontinuation;
• Delayed postoperative medication;
• Restrictive treatment contracts;
• Repeated drug testing;
• Mandatory pill counts;
• One-pharmacy requirements;
• Refusal because of cannabis use;
• Mandatory procedures as a condition of medication;
• Discharge after disagreement;
• Insurance denials;
• Pharmacy-stock limitations;
• Treatment based on a numerical threshold rather than individual circumstances.

No single one of those outcomes proves misconduct by the Detroit Division.

They remain relevant to DEA’s federal mission because the agency has expressly accepted responsibility for preserving an adequate and uninterrupted supply for legitimate medical needs.

A control system cannot evaluate itself solely by counting what it prevented.

It must also examine what lawful care remained available.

CDC’s Current Clinical Position

CDC’s 2022 opioid-prescribing guideline provides voluntary clinical recommendations intended to support flexible, individualized, patient-centered decision-making.

CDC states that the guideline:

• Is not a replacement for clinical judgment;
• Is not intended to become an inflexible standard;
• Should not cause rapid tapering or abrupt discontinuation;
• Is not itself a law, regulation, or policy;
• Does not apply to pain related to sickle-cell disease, cancer, palliative care, or end-of-life care.

These limitations matter because recommendations can change character as they move through institutions.

A clinical consideration can become a corporate ceiling.

A dosage guidepost can become a boundary that was never written into law.

A population-level risk association can become an individual presumption.

A recommendation to proceed carefully can become a demand to stop treatment.

When that occurs, the resulting policy should be judged on its own terms rather than defended solely by invoking CDC.

Prescribing and Dose-Decline Context

Why There Is No Honest 1984-to-Present Line

No single official dataset measures opioid prescribing in Michigan, Ohio, and northern Kentucky continuously from 1984 through 2026 using one stable definition.

The historical record changes:

• Geography;
• Population;
• Data source;
• Sampling method;
• Drug category;
• Unit of measurement;
• Prescriber setting;
• Pharmacy setting.

Different records measure:

• Drug mentions during physician visits;
• Number of prescriptions;
• Prescriptions per 100 residents;
• Morphine milligram equivalents;
• Average daily dosage;
• High-dose prescriptions;
• Long-acting or extended-release prescriptions;
• Days supplied;
• Medicare claims;
• Medicaid claims;
• Particular patient populations.

Those measures cannot be fused into one uninterrupted line without misleading the reader.

The responsible method is to preserve each measure under its original definition and acknowledge every gap.

1984: Historical Analgesic Utilization

On March 14, 1984, the National Center for Health Statistics published Utilization of Analgesic Drugs in Office-Based Ambulatory Care: National Ambulatory Medical Care Survey, 1980–81.

The report described analgesic drug mentions during office-based physician encounters.

It was not a Detroit Division study.

It did not produce a Michigan, Ohio, or northern Kentucky retail-opioid-dispensing rate.

It did not use the modern measure of prescriptions per 100 residents.

It nevertheless provides a defensible historical point showing that federal health researchers were examining analgesic use in ordinary medical practice during the early 1980s.

That record belongs in the chronology.

It must not be mathematically merged with modern pharmacy data.

Michigan and Ohio Retail Dispensing Rates

The following table reports retail opioid prescriptions dispensed per 100 persons.

The 2006–2018 figures come from CDC’s historical state dispensing tables. The 2023 values come from an independently preserved copy of CDC’s November 2024 state table.

No values were interpolated for missing years.

Year	Michigan	Ohio
2006	80.2	87.7
2007	85.6	92.7
2008	89.9	97.5
2009	91.6	100.4
2010	96.0	102.4
2011	98.8	101.5
2012	100.7	97.5
2013	98.9	93.1
2014	98.0	89.5
2015	90.5	82.7
2016	84.9	75.3
2017	75.5	63.8
2018	62.7	53.5
2023	47.9	40.7

The 2006–2009 values are taken from CDC’s archived annual state tables.

The 2010–2013 values document the period in which Michigan and Ohio reached the highest values shown in their respective series.

The 2014–2018 values document sustained declines in both states.

The preserved 2023 table reports Michigan at 47.9 and Ohio at 40.7 prescriptions per 100 residents.

What the Michigan Series Shows

Michigan rose from 80.2 prescriptions per 100 persons in 2006 to a series high of 100.7 in 2012.

By 2018, the rate had fallen to 62.7.

By 2023, it had fallen to 47.9.

That represents an approximate 52 percent decline from the 2012 peak.

The change was not a brief fluctuation.

It was a sustained transformation in the amount of opioid prescribing recorded through the retail-pharmacy series.

The rate does not explain why each prescription was written or why each later prescription disappeared.

What the Ohio Series Shows

Ohio rose from 87.7 prescriptions per 100 persons in 2006 to a series high of 102.4 in 2010.

By 2018, the rate had fallen to 53.5.

By 2023, it had fallen to 40.7.

That represents an approximate 60 percent decline from the 2010 peak.

Ohio’s decline began earlier than Michigan’s and continued across the remainder of the series shown.

The scale of the reduction demonstrates major change.

It does not independently prove whether that change produced better medicine, inadequate medicine, or some combination of beneficial and harmful outcomes.

Why Kentucky Is Not in the Table

The Detroit Division serves only northern Kentucky, not the entire state.

The public sources reviewed for this page do not provide an exact county boundary suitable for aggregating county-level prescribing data.

A statewide Kentucky rate would include large areas outside the Detroit Division.

Presenting it beside Michigan and Ohio without that qualification would create a false geographical equivalence.

Accordingly:

• No statewide Kentucky rate is labeled as a Detroit Division rate;
• No northern Kentucky rate is estimated;
• No counties are selected by assumption;
• No missing years are interpolated.

The absence of a defensible number is reported as an evidence limitation.

It is not filled with a convenient approximation.

2019 Through 2024

CDC’s current retail-pharmacy series reports that the national opioid-dispensing rate declined from 46.8 prescriptions per 100 persons in 2019 to 35.4 in 2024.

CDC states that the underlying IQVIA Xponent data are based on approximately 54,600 non-hospital retail pharmacies representing nearly 94 percent of United States retail prescriptions.

The data include new and refilled retail prescriptions paid through commercial insurance, Medicare, Medicaid, cash, and other sources.

They exclude mail-order prescriptions.

Geography is assigned by prescriber location rather than necessarily the patient’s residence or the dispensing pharmacy.

Methadone dispensed through opioid-treatment programs is excluded.

The state and national numerators are projected estimates, while population denominators come from Census estimates.

CDC’s current interactive presentation contains state information through 2024. During this review, the static citable text did not expose stable individual 2024 rows for Michigan and Ohio.

This page therefore reports:

• The verified national series through 2024;
• The recoverable Michigan and Ohio state series through 2023;
• No guessed 2024 state values.

An unavailable number is not permission to create one.

The Central Statistical Finding

Michigan and Ohio both experienced major increases during the early portion of the available CDC series, followed by sustained and substantial declines.

From their reported peaks to 2023:

• Michigan declined approximately 52 percent.
• Ohio declined approximately 60 percent.

Those reductions represent one of the largest transformations in modern regional medical practice.

The figures establish the direction and scale of change.

They do not identify how much of the decline resulted from:

• DEA enforcement;
• State prescribing laws;
• Prescription-monitoring programs;
• CDC guidance;
• Medical-board expectations;
• Insurance policies;
• Corporate pharmacy restrictions;
• Hospital policies;
• Civil litigation;
• Voluntary clinical judgment;
• Patient preferences;
• Changes in the illicit drug market.

Those causal questions require different evidence.

What the Statistics Prove

The available record proves that:

• Opioid dispensing rose substantially in Michigan and Ohio during the early years of the CDC series;
• Ohio reached its reported peak in 2010;
• Michigan reached its reported peak in 2012;
• Both states experienced sustained declines afterward;
• Michigan’s rate fell by approximately half from its peak;
• Ohio’s rate fell by approximately three-fifths from its peak;
• National retail dispensing continued to decline through 2024;
• Statewide Kentucky data cannot be treated as a northern Kentucky divisional rate;
• Different historical measures cannot be merged into one seamless 1984-to-present line.

What the Statistics Cannot Prove

The data cannot prove that every prescription removed from the system was unnecessary.

They cannot prove that every prescription remaining in the system was appropriate.

They cannot determine whether an individual patient:

• Could walk;
• Could sleep;
• Could work;
• Could recover from surgery;
• Could care for family;
• Could remain independent;
• Received enough medicine;
• Received too much medicine;
• Was abandoned;
• Was involuntarily tapered;
• Could locate a pharmacy;
• Could find a willing practitioner.

The data do not count prescriptions that were never written because a physician refused to accept the patient.

They do not count lawful prescriptions that a pharmacy declined to fill.

They do not identify every medication shortage.

They do not directly measure:

• Pain severity;
• Functional ability;
• Quality of life;
• Suicide;
• Untreated suffering;
• Adequacy of postoperative care;
• Whether an individual prescribing decision was medically justified.

The numbers measure portions of medicine distributed.

They do not fully measure the human consequences of what was withheld.

Seeds of Vice Analysis

What the Official Record Proves

The Detroit Division is a regional command serving Michigan, Ohio, and a presently undefined portion of northern Kentucky.

DEA’s own public pages do not describe that jurisdiction consistently.

Joseph O. Dixon is the current Special Agent in Charge. His professional background is rooted in criminal investigations, violent-crime initiatives, international liaison work, professional responsibility, task-force management, and field-office leadership.

The division has publicly identified Tactical Diversion Squads in Detroit, Cleveland, and Columbus.

Those squads possess access to conventional law-enforcement methods including surveillance, confidential sources, controlled evidence purchases, warrants, arrests, and evidence seizure.

The official record also proves that diversion from the lawful medical channel is real.

Pharmacies can fail to account for controlled inventory.

Treatment facilities can fail to maintain required controls.

Corporate dispensing systems can process prescriptions alleged to be invalid.

Physicians can prescribe outside professional practice or misuse another person’s registration.

Those are legitimate subjects of investigation.

The record equally proves that DEA’s official mission includes preserving an adequate and uninterrupted supply for legitimate medical needs.

That responsibility is not secondary language to be ignored when evaluating enforcement.

What the Record Suggests

The Detroit Division’s structure suggests that pharmaceutical enforcement is an established regional function rather than an occasional assignment.

Michigan and Ohio each contain dedicated Tactical Diversion Squad infrastructure.

The division’s jurisdiction combines major metropolitan healthcare systems with rural and medically isolated communities.

That geography likely creates unequal consequences when a pharmacy, practitioner, distributor, or treatment service leaves the lawful channel.

The loss of one provider in Detroit, Cleveland, or Columbus may be burdensome.

The loss of one provider in the Upper Peninsula, rural Michigan, Appalachian Ohio, or a medically underserved border community may eliminate the nearest practical source of care.

That is an inference requiring better public measurement, not a claim that every closure was improper.

The prescribing record also suggests a profound shift in institutional risk tolerance.

Michigan and Ohio reduced retail opioid dispensing by approximately half or more from their respective peaks.

No single investigation, doctor, agency, guideline, or state law can reasonably explain a change of that scale across more than a decade.

The evidence supports an inference of systemic change.

DEA enforcement formed part of that environment.

So did state monitoring systems, medical boards, legislation, insurers, hospital systems, corporate pharmacies, litigation, CDC recommendations, professional culture, and changing illicit markets.

The available record does not quantify the contribution of each institution.

The patient experiences their combined result.

What Seeds of Vice Concludes

Diversion control has a legitimate purpose.

A missing hospital vial is not lawful medicine.

A falsified inventory is not clinical judgment.

Using another person’s DEA registration number is not patient care.

Dispensing without effective controls against known diversion is not harmless.

Investigating those acts protects patients and preserves the lawful channel.

The patient who legitimately needs a controlled medicine is also part of that lawful channel.

That patient is not an unfortunate exception to the system.

The patient is one of the reasons the system exists.

The Detroit Division should therefore be judged by both halves of DEA’s official mission.

Does it detect and stop actual diversion?

Does it preserve adequate and uninterrupted access for legitimate medical needs?

Does it distinguish documented fraud from an unusual but lawful treatment plan?

Does it recognize the difference between physical dependence and criminal conduct?

Does it measure how enforcement affects practitioners who have committed no crime?

Does it identify when hospitals, insurers, clinics, or pharmacies impose restrictions federal law never required?

Does it account for the added vulnerability of rural communities and geographically isolated patients?

Does it protect patients from theft without treating every patient as a likely source of theft?

Does it regard a descending prescription line as evidence requiring interpretation—or as proof of success by itself?

Control alone is not enough.

Availability alone is not enough.

A system that permits uncontrolled theft, fraud, falsification, and unlawful distribution is unsafe.

A system in which lawful medicine exists in statutes and warehouses but cannot be obtained by legitimate patients is also unsafe.

The proper standard is lawful control and lawful availability.

Michigan and Ohio have experienced extraordinary reductions in opioid dispensing.

The burden is not merely to display the descending line and call it progress.

The burden is to prove what improved, who was protected, what harms were prevented, what harms were created, and whether the harmless patient left without medicine still had a lawful place to go.

Contact Information

Headquarters

DEA Detroit Division
431 Howard Street
Detroit, Michigan 48226

Main telephone: (313) 234-4000

Media and Community Outreach

Brian McNeal
(571) 362-1498
Brian.K.McNeal@dea.gov

Special Agent Recruitment

(571) 362-1858
DetroitSpecialAgentRecruiter@dea.gov

Internships and Volunteer Opportunities

Kimberly A. Tozer
(571) 362-1858

Michigan Public Contacts

Flint: (810) 768-7600
Grand Rapids: (616) 458-0616
Kalamazoo: (571) 362-0443
Lansing: (571) 362-1194
Marquette: (571) 362-0443
Traverse City: (571) 362-0443

Ohio Public Contacts

Cincinnati: (513) 684-3671
Cleveland: (216) 274-3600
Columbus: (614) 255-4200
Dayton: (937) 291-1988
Toledo: (419) 259-6490
Youngstown: (330) 740-7000

Northern Kentucky

DEA’s current leadership and operational records include northern Kentucky within the Detroit Division.

The public Detroit page does not publish a Kentucky office or direct northern Kentucky contact.

The Detroit headquarters is therefore the most defensible published contact for division-level inquiries concerning that portion of the jurisdiction.

Sources and Methodology

This page was assembled primarily from current official records published by:

• The Drug Enforcement Administration;
• DEA’s Diversion Control Division;
• The United States Department of Justice;
• The Centers for Disease Control and Prevention;
• The Michigan Department of Licensing and Regulatory Affairs;
• The State of Ohio Board of Pharmacy;
• Kentucky public-health and controlled-substance authorities.

Official DEA sources were compared with one another rather than assumed to be internally consistent.

Where DEA’s main division page described only Michigan and Ohio but current leadership and operational records included northern Kentucky, the conflict was disclosed.

No exact northern Kentucky county boundary was invented.

No Kentucky office, contact number, staffing level, or organizational classification was inferred without an official source.

Personnel were included only when current official pages identified them publicly.

No complete employee roster was constructed from social-media profiles, commercial databases, stale releases, or former assignments.

Enforcement matters were described according to their legal posture.

Allegations were identified as allegations.

Consent decrees and civil settlements were not described as criminal convictions.

A jury conviction was identified as a proven criminal outcome rather than an unresolved accusation.

State prescription-monitoring programs were not mislabeled as DEA databases.

Historical prescribing measures were kept separate according to their original definitions.

No interpolation was performed across missing years.

Drug mentions during office visits were not treated as retail prescriptions.

Prescription counts were not treated as dosage.

State dispensing rates were not treated as individual medical judgments.

Michigan and Ohio statewide figures were presented because the complete states fall within the division.

Statewide Kentucky data were excluded because the division serves only northern Kentucky and the reviewed public record does not provide a defensible county boundary.

The national retail-pharmacy series is presented through 2024.

The individual Michigan and Ohio series is presented through the latest stable values used here: 2023.

An unavailable number is reported as unavailable.

It is not replaced with a convenient estimate.

Verification date: July 24, 2026